Novartis NOVN1.25%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS 0.25%increase; green up pointing triangle for a total equity value of up to roughly $1.7 billion.

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Regulus and Nuton will jointly undertake copper sulphide leach testing utilizing Nuton’s copper sulphide leach technologies with samples from AntaKori The Nuton™ technologies have the ...

(RTTNews) - Regulus Therapeutics (RGLS) has entered into an agreement and plan of merger with Novartis AG and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will ...

April 30 (Reuters) - Novartis (NOVN.S), opens new tab has agreed to buy Regulus Therapeutics (RGLS.O), opens new tab for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone ...

Novartis has agreed to acquire Regulus Therapeutics for a total equity value of up to roughly $1.7 billion. With the merger, the Swiss pharmaceutical company aims to bring to more patients ...